Archive for the ‘Orexigen Therapeutics Inc’ Category

Orexigen Therapeutics Inc

October 5th, 2015 | Posted in 2015, Orexigen Therapeutics Inc

Orexigen Therapeutics Inc, San Diego, filed a new drug application for Contrave as a monotherapy for weight management in overweight or obese adult patients, with the Ministry of Food and Drug Safety in South Korea. If approved, Kwang Dong Pharmaceutical, Seoul, South Korea, will market and distribute the therapy as part of a distribution deal.

Orexigen Therapeutics

May 11th, 2015 | Posted in 2015, Orexigen Therapeutics Inc

Orexigen Therapeutics, San Diego, is authorized to begin selling its anti-obesity treatment in all 28 members states of the European Union. The drug will be marketed as Mysimba in Europe and is known as Contrave in the U.S.

Orexigen Therapeutics Inc

September 7th, 2010 | Posted in Orexigen Therapeutics Inc

Orexigen Therapeutics Inc has entered into an exclusive partnership with Osaka-based Takeda Pharmaceutical Company Limited to develop and commercialize Orexigen’s investigational obesity drug, “Contrave,” in the USA, Canada and Mexico.  Under the Agreement, Orexigen will receive an upfront cash payment of $50-million from Takeda, and Takeda will obtain an exclusive marketing right for the USA […]